|Monitoring:||Baseline labs: PT, PTT, CBC (Hgb, Hct, platelet
QOD labs: Hgb, Hct.
Daily labs: platelet count, PTT. The patient should be monitored daily for signs / symptoms of bleeding.
|Mechanism of action||Heparin acts as a catalyst to accelerate the rate at which antithrombin III neutralizes thrombin and other activated clotting factors.|
|Half-life||0.4 to 2.5 hours (Usual: 1.5 hrs)|
|Heparin resistance||Patients with familial antithrombin III deficiency. Also patients with fever, post-op, some with PE, MI, thrombophlebitis, infections with thrombosing tendencies or extensive thrombotic disorders, especially in conjunction with malignant neoplasms.|
|Heparin-induced thrombocytopena||Two forms of H.I.T exist.
(1) Early benign, reversible, non-immune thrombocytopenia.
(2) Late, more serious IgG-mediated version which can cause a profound drop in the platelet count.
H.I.T. usually begins between 5 to 15 days after therapy, but it
can occur within hours of starting therapy in patients who have received